In vitro studies indicated that the subfraction of ROSlow AML CD34+ cells had the highest autophagic flux and were more susceptible to HCQ treatment when compared with ROShigh AML CD34+ cells. The gene discussed is CD34; the disease is acute myeloid leukemia.